Entero Healthcare Q2FY27 revenue up 33% to Rs. 2,087.1 crore, PAT up 66%; targets Rs. 1,000 crore MedTech revenue in FY27
Q2FY27 revenue up 33% to Rs. 2,087.1 crore, EBITDA up 78% to Rs. 110.7 crore and profit after tax up 66% to Rs. 60.7 crore.
By ScoutQuest · · 1 min read
- Q2FY27 consolidated revenue
- Rs. 2,087.1 crore, up 33% from Rs. 1,570.9 crore a year earlier
- EBITDA
- Rs. 110.7 crore, up 78% at a 5.3% margin versus 4.0%
- Profit after tax
- Rs. 60.7 crore, up 66%
- Period
- Q2FY27 and H1FY27
- Positioning
- Entero presents itself as a scaled pharmaceutical and MedTech distributor built on acquisitions: Rs. 6,591 crore FY26 revenue, over 105,300 retail customers, 97,500+ SKUs, 136 warehouses across 523 districts and 51 acquisitions since incept
📈 Q2FY27 consolidated revenue was Rs. 2,087.1 crore, up 33% from Rs. 1,570.9 crore a year earlier, with EBITDA up 78% to Rs. 110.7 crore at a 5.3% margin versus 4.0% and profit after tax up 66% to Rs. 60.7 crore; finance costs rose to Rs. 20.3 crore from Rs. 9.7 crore.
📈 The revenue split slide prints 18.2% organic growth and 20.0% like-for-like growth for Q2FY27, with 14.7% inorganic growth coming entirely from calendarisation; total growth was 32.9% and the company says it grew 1.3x the IPM market.
📈 For the full FY26 year the deck prints revenue of Rs. 6,591.2 crore (FY25 Rs. 5,095.8 crore), EBITDA of Rs. 266.0 crore and profit after tax of Rs. 145.8 crore, a year that includes a Rs. 8.2 crore one-off exceptional item described as the impact of the New Labour Code in India.
📈 Management states FY27 MedTech revenue is expected to cross Rs. 1,000 crore and that the current business and acquisitions are focused on IVD and Cardiology/Orthopedic devices; the presentation lists 51 acquisitions since inception under a pan-India integration approach.
Also from Entero Healthcare Solutions
Wholly owned subsidiary's customer defaults on INR 11.87 crore dues; entire amount provisioned
4 Nov 2026
Board approves Q2/H1 FY27 results with unmodified limited review; notes grant of 49,712 fresh ESOPs
4 Nov 2026
Q2 results with unmodified limited review, plus 49,712 fresh ESOPs
4 Nov 2026
More numbers
- Revenue, Q2FY272,087.1 (Rs. Cr)
- Revenue, Q2FY261,570.9 (Rs. Cr)
- EBITDA, Q2FY27110.7 (Rs. Cr)
- Profit after tax, Q2FY2760.7 (Rs. Cr)
- Revenue year-on-year growth, Q2FY2733%
- EBITDA margin, Q2FY275.3%
- Revenue, H1FY274,027.6 (Rs. Cr)
- Revenue, FY266,591.2 (Rs. Cr)
- Organic growth like-for-like, Q2FY2720.0%
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.